GE HealthCare (GEHC) reported revenue growth in the first quarter of 2025 compared to last year, but estimated a drop in profits due to new tariffs moving ahead.
The company posted revenues of $4.8 billion in the first quarter (end-March 31), an increase of 3% compared with $4.65 billion in the first quarter last year. In addition, total company orders increased a record 10% organically in the first quarter over the same quarter last year, the company said.
Net income attributable to GEHC was $564 million in the first quarter versus $374 million in the same quarter last year, while adjusted EBIT was $715 million versus $681 million, the company said. GEHC’s cash flow from operating activities was $250 million, down $169 million from the first quarter last year.
On an individual segment basis, GE HealthCare's imaging segment had revenues of $2.14 billion, up 4% from $2 billion reported in the first quarter of 2023. Meanwhile, the company’s advanced visualization solution segment generated revenues of $1.24 billion, up 1% from $1.23 billion in the first quarter last year, while its Pharmaceutical Diagnostics revenue increased to $632 million, up 6% from $599 million last year, GEHC reported.
The company noted it is continuing to focus on advancing its cardiology care pathway, and is making progress on the roll out of Flyrcado (flurpiridaz F-18) in the U.S. after its launch in April, including establishing a nationwide contract manufacturing network and steadily increasing doses, while building our customer base.
Regarding the current global trade environment, the company said it is actively driving mitigation actions due to new tariffs. The company still expects to grow sales by 2% to 3% in 2025 compared to 2024, but estimates profit margins to drop to 14.2% to 14.4%, down from 16.3% last year.
